- Zacks Small Cap Research•15 days ago
On April 6, 2017, Ceapro Inc. (CZO.V) released full-year 2016 financial and operational results. 2016 revenues of $13.7 million rose 28% over the prior year and earnings of 5.1c posted a near 50% increase on an adjusted basis. These results are below our estimates of $14.7 million in revenues and earnings of 6.2c (note that all currency herein is denominated in Canadian dollars). By geography, on a year over year basis, 2016 sales increases in the US, Canada, Germany and Other were offset by declines in China. In the fourth quarter, sales fell 29% vs. Q4:15 as Germany and China did not maintain previous year sales’ levels. The 4Q:16 vs. 4Q:15 difference was also attributable to a significant reduction in orders for beta glucan. Sequentially, Ceapro experienced quarterly declines in US, Germany, and Canada but increases in China and Other regions.
- Marketwired•21 days ago
Ceapro Inc. , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced its financial results for ...
- Accesswire•21 days ago
LONDON, UK / ACCESSWIRE / April 6, 2017 / Active Wall St. announces the list of stocks for today's research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected ...
CZO.V : Summary for Ceapro Inc - Yahoo Finance
Ceapro Inc. (CZO.V)
TSXV - TSXV Delayed Price. Currency in CAD
Add to watchlist
|Day's Range||1.29 - 1.35|
|52 Week Range||0.70 - 2.47|
|PE Ratio (TTM)||25.49|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|